IP Library › Granted Patent US 10,238,739
Granted Patent B2
US 10,238,739 · App. 15/531,487 · Granted Mar 26, 2019

Manufacture of surfactant-containing compositions with enhanced stability

Inventor: Gottfried Kraus (Marburg, DE)
Assignee: NOVARTIS AG
A61K39/39A61K39/00A61K39/145B01D71/68C12N7/00A61K2039/55566B01D2325/022B01D2325/36C12N2760/16034
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,238,739
App. No.
15/531,487
Granted
Mar 26, 2019
Kind
B2
Abstract

Improved methods for the manufacture of pharmaceutical compositions comprising at least one surfactant, involving prefiltration of the surfactant prior to formulation into final products.

Claims (20)

1. A process for preparing an oil-in-water emulsion comprising steps of:

(a) purifying polysorbate 80 by filtering polysorbate 80 through a filter having a pore size between 5-50 μm; and

(b) forming the oil-in-water emulsion by either:

i) combining the purified polysorbate 80 with an aqueous component and adding an oil component; or

ii) combining the purified polysorbate 80 with an oil component and adding an aqueous component.

2. The process of claim 1 , wherein the filter is a polypropylene filter.

3. The process of claim 1 , wherein the oil-in-water emulsion formed in step (b) is homogenized.

4. The process of claim 1 , wherein the oil-in-water emulsion formed in step (b) is microfluidized.

5. The process of claim 3 , wherein step (b) further comprises sterile filtration of the homogenized oil-in-water emulsion.

6. The process of claim 1 , wherein the oil-in-water emulsion is a vaccine adjuvant including squalene.

7. The process of claim 6 , wherein the oil-in-water emulsion comprises squalene, the polysorbate 80, and sorbitan trioleate.

8. The process of claim 1 , wherein the oil-in-water emulsion has less than 0.85 ppm acetaldehyde.

9. The process of claim 1 , wherein the oil-in-water emulsion comprises squalene and the emulsion has less than 661 picograms of polychlorinated biphenyls per gram of squalene (toxic equivalent TEQ).

10. A method for preparing (i) a vaccine composition, comprising preparing an oil-in-water emulsion according claim 1 and combining the emulsion with an antigen, or (ii) a vaccine kit comprising preparing an oil-in-water emulsion according to claim 1 and packaging the emulsion into a kit as a kit component together with an antigen component.

11. The method of claim 10 , wherein the antigen is an influenza virus antigen.

12. The process of claim 4 , wherein step (b) comprises sterile filtration of the microfluidized emulsion.

13. The method of claim 11 , wherein the combination of the emulsion and the antigen forms a vaccine composition and wherein the vaccine composition includes about 15 μg, about 10 μg, about 7.5 μg, about 5 μg, about 3.8 μg, about 1.9 μg, or about 1.5 μg of hemagglutinin per influenza virus strain.

14. A process for preparing an oil-in-water emulsion comprising steps of:

(a) purifying a composition comprising polysorbate 80 and an aqueous component by filtering the composition through a filter having a pore size between 5-50 μm; and

(b) forming the oil-in-water emulsion by combining the purified composition comprising polysorbate 80 and the aqueous component with an oil component.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2024
From: NOVARTIS AG
To: SEQIRUS UK LIMITED
Reel/Frame 069642/0293 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2017
From: KRAUS, GOTTFRIED
To: NOVARTIS VACCINES AND DIAGNOSTICS GMBH
Reel/Frame 042524/0772 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2017
From: NOVARTIS VACCINES AND DIAGNOSTICS GMBH
To: NOVARTIS AG
Reel/Frame 042524/0859 →
Priority Claims (1)
EP 14195981 · Dec 2, 2014 · regional
Continuity (1)
Related Publication 20170312357A1 · Nov 2, 2017